People

On October 2, Roy Jensen, MD, began a 2-year term as president of the Association of American Cancer Institutes. Jensen serves as director of The University of Kansas Cancer Center and the Kansas Masonic Cancer Research Institute, both in Kansas City. He is also a professor of pathology and laboratory medicine, as well as anatomy and cell biology, at The University of Kansas Medical Center in Kansas City. Jensen's research focuses on BRCA1 regulation, expression, and function in breast cancer, and he was part of the team that established BRCA1 as a tumor suppressor.

Steven Artandi, MD, PhD, started his position as director of the Stanford Cancer Institute in California on October 1, succeeding Beverly Mitchell, MD. Previously, Artandi was a professor of medicine and biochemistry at the Stanford University School of Medicine. Artandi is also on the board of directors for Axsun Technologies. He has served as senior editor of Molecular Cancer Research (MCR) and is currently on the editorial boards of MCR and Stem Cells. Artandi's laboratory focuses on the role of telomerase in cancer, aging, and stem cell biology.

Padmanee Sharma, MD, PhD, professor of genitourinary medical oncology and immunology at The University of Texas MD Anderson Center in Houston, won the Cancer Research Institute's 2018 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. Sharma studies immune checkpoint inhibitors: She led clinical trials on bladder and prostate cancers that established the importance of the ICOS molecular pathway for promoting tumor destruction after anti-CTLA4 therapy. She is also investigating combinations of immune checkpoint inhibitors for prostate cancer.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.